Application Note: Drug Discovery in 3D

Several studies highlighting how organoids are being used for drug discovery purposes.

Drug development is an inherently lengthy and costly process that has a high rate of candidate attrition. The high attrition is in large part due to the poor translatability of preclinical data, including from early-stage in vitro drug screens, where 2D cell line cultures have traditionally dominated. While 2D cultures can be used to rapidly generate large datasets (since they are easy to manipulate and comparatively inexpensive), they fall short when it comes to clinical predictivity. While primary cell cultures are certainly more clinically and physiologically relevant than 2D cell lines, they have some limitations, particularly related to their variable reproducibility and that they are not consistently scalable or available to meet the demands of high-throughput drug screens.

Optimized Hubrecht Organoid Technology (HUB) protocols have been established to develop 3D in vitro organoids, from healthy and diseased tissue. They are superior models for in vitro drug screens and provide the best chance for drug candidates’ translatability, as they:

• Rely upon clinically relevant models that have been shown to be predictive of patient drug response, and
• Are highly reproducible, with low batch-to-batch variation even after long-term culturing and cryopreservation.

Download This Application Note to Learn About:

• Image-based phenotypic analysis in 3D for visualization and quantification of the effects of targeted therapies on cells
• Tumor organoid matrix screens to assess potential synergistic effects of combination therapy
• Tumor organoid killing with CAR-T cell co-cultures

Download The Application Note Now!